Phase Ib study of pembrolizumab in combination with trastuzumab emtansine for metastatic HER2-positive breast cancer

BACKGROUND: Preclinical and clinical data support potential synergy between anti-HER2 therapy plus immune checkpoint blockade. The safety and tolerability of trastuzumab emtansine (T-DM1) combined with pembrolizumab is unknown. METHODS: This was a single-arm phase Ib trial (registration date January...

Descripción completa

Detalles Bibliográficos
Autores principales: Waks, Adrienne G, Keenan, Tanya E, Li, Tianyu, Tayob, Nabihah, Wulf, Gerburg M, Richardson, Edward T, Attaya, Victoria, Anderson, Leilani, Mittendorf, Elizabeth A, Overmoyer, Beth, Winer, Eric P, Krop, Ian E, Agudo, Judith, Van Allen, Eliezer M, Tolaney, Sara M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9577940/
https://www.ncbi.nlm.nih.gov/pubmed/36252998
http://dx.doi.org/10.1136/jitc-2022-005119

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9577940/
https://www.ncbi.nlm.nih.gov/pubmed/36252998
http://dx.doi.org/10.1136/jitc-2022-005119

Ejemplares similares